Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Public ClinicalTrials.gov record NCT04603924. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3 Randomized and Placebo-Controlled Study of ANA001 in Moderate and Severe COVID-19 Patients
Study identification
- NCT ID
- NCT04603924
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- NeuroBo Pharmaceuticals Inc.
- Industry
- Enrollment
- 49 participants
Conditions and interventions
Conditions
Interventions
- Niclosamide Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 6, 2020
- Primary completion
- Feb 15, 2022
- Completion
- Feb 15, 2022
- Last update posted
- May 14, 2025
2020 – 2022
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Helen Keller Hospital | Sheffield | Alabama | 35660 | — |
| University of California, Irvine | Irvine | California | 92697 | — |
| Baptist Health Research Institute | Jacksonville | Florida | 32207 | — |
| AdventHealth Tampa | Tampa | Florida | 33613 | — |
| University of Missouri Health Care | Columbia | Missouri | 65212 | — |
| Caroline Institute for Clinical Research | Fayetteville | North Carolina | 28303 | — |
| Memorial Hermann Memorial City Medical Center | Houston | Texas | 77024 | — |
| Providence Regional Medical Center Everett | Everett | Washington | 92801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04603924, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04603924 live on ClinicalTrials.gov.